Table 2.
Univariate COX regression analysis for the risk factors for progression (PFS) and time-to-failure (TTF) in Fulvestrant users
| Covariates | Level | PFS | TTF | ||
|---|---|---|---|---|---|
| Hazard ratio (95% CI) | p-value | Hazard ratio (95% CI) | p-value | ||
| Fulvestrant usage | First line | Ref | Ref | ||
| Second line | 1.911 (0.803, 4.547 | 0.14 | 2.008 (0.849, 4.745) | 0.11 | |
| ≥ Third line | 2.420 (1.026, 5.711) | 0.04 | 2.668 (1.135, 6.272) | 0.03 | |
| Age at diagnosis (years) | 1.001 (0.977, 1.026) | 0.94 | 1.004 (0.981, 1.028) | 0.72 | |
| Age at FX usage (years) | 0.990 (0.966, 1.015) | 0.44 | 0.994 (0.971, 1.017) | 0.60 | |
| < 62 | Ref | Ref | |||
| ≥ 62 | 0.753 (0.441, 1.288) | 0.30 | 0.714 (0.425, 1.199) | 0.20 | |
| Weight | 0.999 (0.982, 1.016) | 0.37 | 0.997 (0.979, 1.015) | 0.75 | |
| DFS (years) | 0.950 (0.886, 1.019) | 0.15 | 0.948 (0.887, 1.013) | 0.11 | |
| ER | Negative | 0.610 (0.128, 2.903) | 0.53 | 0.795 (0.168, 3.763) | 0.77 |
| 1%–50% | Ref | Ref | |||
| 50%–100% | 0.693 (0.318, 1.510) | 0.36 | 0.869 (0.404, 1.869) | 0.72 | |
| Unknown | 0.706 (0.326, 1.528) | 0.71 | 0.894 (0.417, 1.916) | 0.77 | |
| PR | Negative | Ref | Ref | ||
| Positive | 1.171 (0.602, 2.277) | 0.64 | 1.073 (0.582, 1.981) | 0.82 | |
| HER2 | Negative | Ref | Ref | ||
| Positive | 2.024 (0.997, 4.109) | 0.05 | 1.833 (0.936, 3.587) | 0.08 | |
| Nuclear or histological grade | 2 | Ref | Ref | ||
| 3 | 1.683 (0.942, 3.004) | 0.08 | 1.476 (0.861, 2.530) | 0.15 | |
| Unknown | 1.410 (0.782, 2.541) | 0.25 | 1.219 (0.694, 2.139) | 0.49 | |
| Stage at BC diagnosis | 0/I | Ref | Ref | ||
| II | 1.476 (0.791, 2.755) | 0.22 | 1.378 (0.759, 2.503) | 0.29 | |
| III/IV | 1.709 (1.001, 2.919) | 0.05 | 1.607 (0.969, 2.666) | 0.07 | |
| Menopause | Natural menupause | Ref | Ref | ||
| OFS (OFS + surgery) | 0.850 (0.463, 1.560) | 0.60 | 0.697 (0.384, 1.265) | 0.24 | |
| Surgery | 1.145 (0.673, 1.948) | 0.62 | 1.049 (0.624, 1.764) | 0.86 | |
| Treatment of primary diagnosis | Primary site surgery | 0.807 (0.112, 5.837) | 0.83 | 0.515 (0.126, 2.107) | 0.36 |
| Primary site Radiation | 1.075 (0.688, 1.682) | 0.75 | 1.133 (0.738, 1.740) | 0.57 | |
| Chemotherapy | 0.995 (0.495, 2.003) | 1.00 | 0.968 (0.499, 1.881) | 0.92 | |
| Endocrine therapy | 1.223 (0.729, 2.049) | 0.45 | 1.263 (0.771, 2.068) | 0.35 | |
| Treatment after relapse or metastasis | Radiation (Yes vs No) | 1.091 (0.589, 2.022) | 0.78 | 0.879 (0.476, 1.621) | 0.68 |
| Chemotherapy (Yes vs No) | 1.394 (0.873, 2.226) | 0.16 | 1.413 (0.905, 2.206) | 0.13 | |
| Metastatic sites | Lymph nodes | 1.623 (1.041, 2.531) | 0.03 | 1.509 (0.986, 2.311) | 0.06 |
| Bone | 1.096 (0.682, 1.762) | 0.83 | 1.180 (0.745, 1.869) | 0.57 | |
| Visceral | 1.036 (0.671, 1.601) | 0.87 | 0.967 (0.637, 1.468) | 0.87 | |